INTRODUCTION {#s1}
============

Chemically defined media for cultivation of yeasts (CDMY) are essential for fundamental and applied research. In contrast to complex media, which contain non-defined components such as yeast extract and/or peptone, defined media enable generation of highly reproducible data, independent variation of the concentrations of individual nutrients, and, in applied settings, design of balanced media for high-biomass-density cultivation and application of defined nutrient limitation regimes ([@B1], [@B2]). CDMY such as yeast nitrogen base (YNB) and Verduyn medium are widely used in research on *Saccharomyces* yeasts ([@B2], [@B3]). In addition to carbon, nitrogen, phosphorous, and sulfur sources and metal salts, these media contain a set of seven growth factors: biotin (B~7~), nicotinic acid (B~3~), inositol (B~8~), pantothenic acid (B~5~), *para*-aminobenzoic acid (*p*ABA) (formerly known as B~10~), pyridoxine (B~6~), and thiamine (B~1~). Based on their water solubility and roles in the human diet, these compounds are all referred to as B vitamins, but their chemical structures and cellular functions are very different ([@B4]). Taking into account their roles in metabolism, they can be divided into three groups: (i) enzyme cofactors (biotin, pyridoxine, and thiamine), (ii) precursors for cofactor biosynthesis (nicotinic acid, *p*ABA, and pantothenic acid), and (iii) inositol, which is a precursor for phosphatidylinositol and glycosylphosphatidylinositol anchor proteins ([@B5]).

Previous studies demonstrated that *Saccharomyces* species are bradytroph for some B vitamins; growth does not strictly depend on addition of all of these compounds, but their omission from CDMY typically results in reduced specific growth rates ([@B6][@B7][@B8]). These observations imply that the term "vitamin," which implies a strict nutritional requirement, is in many cases formally incorrect when referring to the role of these compounds in Saccharomyces cerevisiae metabolism ([@B5]). In view of its widespread use in yeast physiology, we will nevertheless use it in this paper.

The observation that *Saccharomyces* yeasts can *de novo* synthesize some or all of the "B vitamins" included in CDMY is consistent with the presence of structural genes encoding the enzymes required for their biosynthesis ([Fig. 1](#F1){ref-type="fig"} \[[@B5]\]). However, as illustrated by recent studies on biotin requirements of S. cerevisiae CEN.PK113-7D ([@B5], [@B9]), a full complement of biosynthetic genes is not necessarily sufficient for fast growth in the absence of an individual vitamin. In the absence of biotin, this strain grew extremely slowly (μ \< 0.01 h^−1^), but fast biotin-independent growth was obtained through prolonged adaptive laboratory evolution (ALE) in a biotin-free CDMY. Reverse engineering of mutations acquired by evolved strains showed that, along with mutations in the plasma membrane transporter genes *TPO1* and *PDR12*, a massive amplification of *BIO1* was crucial for fast biotin-independent growth of evolved strains ([@B10]). These results illustrated the power of ALE in optimizing microbial strain performance without *a priori* knowledge of critical genes or proteins and in unravelling the genetic basis for industrially relevant phenotypes by subsequent whole-genome sequencing and reverse engineering ([@B11], [@B12]).

![Schematic representation of the *de novo* biosynthetic pathways for the B vitamins biotin (A), nicotinic acid (B), *myo*-inositol (C), pantothenate (D), *p*ABA (E), and pyridoxine and thiamine (F) in S. cerevisiae ([@B5]). Vitamins that are usually added to the chemical defined media for cultivation of yeasts are shown in light blue.](AEM.00388-20-f0001){#F1}

Elimination of vitamin requirements could enable cost reduction in the preparation of defined industrial media, and fully prototrophic strains could provide advantages in processes based on feedstocks whose preparation requires heating and/or acid treatment steps (e.g., lignocellulosic hydrolysates \[[@B13], [@B14]\]) that inactivate specific vitamins. In addition, processes based on vitamin-independent yeast strains may be less susceptible to contamination by vitamin-auxotrophic microorganisms such as lactic acid bacteria ([@B15]). Thus, chassis strains able to grow fast in the absence of single or multiple vitamins would therefore be of interest for industrial application. Moreover, engineering strategies aimed at enabling fast growth and product formation in the absence of single or multiple vitamins may be relevant for large-scale industrial application of *Saccharomyces* yeasts.

The goals of the present study were to investigate whether single-vitamin prototrophy of S. cerevisiae for inositol, nicotinic acid, pantothenic acid, *p*ABA, pyridoxine or thiamine could be achieved by ALE and to identify mutations that support fast growth in the absence of each of these vitamins. To this end, the laboratory strain S. cerevisiae CEN.PK113-7D was subjected to parallel aerobic ALE experiments that encompassed serial transfer in different synthetic media, which each lacked a single B vitamin. Independently evolved strains from each medium type were then characterized by whole-genome resequencing and the relevance of selected identified mutations was assessed by their reverse engineering in the parental non-evolved strain.

(This article was submitted to an online preprint archive \[[@B16]\].)

RESULTS {#s2}
=======

Assessment of CEN.PK113-7D specific B vitamin requirements. {#s2.1}
-----------------------------------------------------------

S. cerevisiae strains belonging to the CEN.PK lineage, which was developed in an interdisciplinary project supported by the German Volkswagen Stiftung between 1993 and 1994 ([@B17]), exhibit properties that make them good laboratory models for yeast biotechnology ([@B18]). To provide a baseline for ALE experiments, specific growth rates of the haploid strain CEN.PK113-7D were analyzed in aerobic batch cultures on complete synthetic medium with glucose (SMD) and on seven "SMDΔ" media from which either biotin, inositol, nicotinic acid, pantothenic acid, *p*ABA, pyridoxine, or thiamine was omitted. To limit interference by carryover of vitamins from precultures, specific growth rates were measured after a third consecutive transfer on each medium ([Fig. 2A](#F2){ref-type="fig"}).

![Specific growth rates of S. cerevisiae CEN.PK113-7D in aerobic batch cultures on complete SMD and on SMD lacking single vitamins. (A) Growth rate measurements were performed after 3 (light gray) and 5 (dark gray) consecutive transfers in the same medium. (B) Growth curves of CEN.PK113-7D in complete SMD (**■**) and at transfer 1 (△) and 3 (▽) in SMD lacking *para*-aminobenzoic acid (*p*ABA). In the latter medium, a lower specific growth rate was observed at transfer 1, but upon the third transfer, the growth rate was the same as in complete SMD. Error bars represent the standard deviations (*n* = 9 for complete SMD; *n* = 3 for all other media).](AEM.00388-20-f0002){#F2}

Consistent with the presence in its genome of genes predicted to encode all enzymes involved in biosynthetic pathways for all seven vitamins ([Fig. 1](#F1){ref-type="fig"} \[[@B5]\]), the strain CEN.PK113-7D grew on all SMDΔ versions. On complete SMD, a specific growth rate of 0.38 ± 0.02 h^−1^ was observed, while specific growth rates on SMDΔ lacking biotin, pantothenate, pyridoxine, thiamine, or inositol were 95%, 57%, 32%, 22%, or 19% lower, respectively. After three transfers, specific growth rates on SMDΔ lacking *p*ABA or nicotinic acid did not differ significantly from the specific growth rate on complete SMD ([Fig. 2A](#F2){ref-type="fig"}). However, in SMDΔ lacking *p*ABA, growth in the first transfer was slower than in the first transfer on complete SMD ([Fig. 2B](#F2){ref-type="fig"}). Extending the number of transfers to five, which corresponded to approximately 33 generations of selective growth, led to higher specific growth rates on several SMDΔ versions ([Fig. 2A](#F2){ref-type="fig"}), suggesting that serial transfer selected for spontaneous faster-growing mutants.

Adaptive laboratory evolution of CEN.PK113-7D for fast growth in the absence of single vitamins. {#s2.2}
------------------------------------------------------------------------------------------------

Serial transfer in independent triplicate aerobic shake-flask cultures on each SMDΔ version was used to select mutants that grew fast in the absence of individual vitamins. Specific growth rates of evolving populations were measured after 5, 10, 23, 38, and 50 transfers and compared to the specific growth rate of strain CEN.PK113-7D grown in complete SMD.

ALE experiments were stopped once the population reached a specific growth rate equal to or higher than 0.35 h^−1^, which represents 90% to 95% of the specific growth rate of strain CEN.PK113-7D on complete SMD ([Fig. 2A](#F2){ref-type="fig"}) ([@B19][@B20][@B22]). As already indicated by the specific growth rates observed after 3 and 5 transfers in SMDΔ ([Fig. 2A](#F2){ref-type="fig"}), few transfers were required for reaching this target in SMDΔ lacking inositol, nicotinic acid, or *p*ABA. Conversely, more than 330 generations of selective growth were required to reach a specific growth rate of 0.35 h^−1^ on SMDΔ lacking either pantothenic acid, pyridoxine, or thiamine ([Fig. 3A](#F3){ref-type="fig"}). At least two single-cell lines were isolated from each of the three independent ALE experiments on each SMDΔ version and the fastest growing single-cell line from each experiment was selected (strains IMS0724 to IMS0726 from SMDΔ lacking nicotinic acid, IMS0727 to IMS0729 from SMDΔ lacking *p*ABA, IMS0730 to IMS0732 from SMDΔ lacking inositol, IMS0733 to IMS0735 from SMDΔ lacking pantothenate, IMS0736 to IMS0738 from SMDΔ lacking pyridoxine, and IMS0747 to IMS0749 from SMDΔ lacking thiamine) ([Table 1](#T1){ref-type="table"}). The specific growth rates of isolates that had been independently evolved in each SMDΔ version did not differ by more than 6%. The largest difference (5.3%) was observed for isolates IMS0733 to IMS0735 evolved on SMDΔ lacking pantothenate ([Fig. 3B](#F3){ref-type="fig"}).

![Heat map showing specific growth rates during ALE of S. cerevisiae CEN.PK113-7D on SMD lacking single vitamins. (A) Aerobic serial transfer experiments on each medium composition were performed in triplicates (rows). The specific growth rate of each evolving population was measured after a specific number of sequential transfers (columns). Yellow color indicates slow growth, while cyan indicates a specific growth rate statistically undistinguishable from that of the positive control (strain CEN.PK113-7D grown on SMD medium with all vitamins). (B) Specific growth rates of single-colony isolates from each independent biological replicate evolution line. The fastest-growing isolates, whose genomes were resequenced, are indicated in blue.](AEM.00388-20-f0003){#F3}

###### 

Specific growth rates of best performing single-colony isolates obtained from serial transfer evolution experiments with S. cerevisiae CEN.PK113-7D on SMD and on SMD variants lacking individual B vitamins

  Strain ID[^*a*^](#T1F1){ref-type="table-fn"}   Evolution condition   Evolution replicate   Growth rate (h^−1^)   \% improvement[^*b*^](#T1F2){ref-type="table-fn"}
  ---------------------------------------------- --------------------- --------------------- --------------------- ---------------------------------------------------
  IMS0721                                        Complete SMD          1                     0.443                 17
  IMS0722                                        Complete SMD          2                     0.423                 11
  IMS0723                                        Complete SMD          3                     0.419                 10
  IMS0747                                        No thiamine           1                     0.383                 35
  IMS0748                                        No thiamine           2                     0.379                 30
  IMS0749                                        No thiamine           3                     0.379                 38
  IMS0736                                        No pyridoxine         1                     0.383                 45
  IMS0737                                        No pyridoxine         2                     0.379                 44
  IMS0738                                        No pyridoxine         3                     0.376                 48
  IMS0733                                        No pantothenate       1                     0.346                 149
  IMS0734                                        No pantothenate       2                     0.384                 155
  IMS0735                                        No pantothenate       3                     0.359                 159
  IMS0724                                        No nicotinic acid     1                     0.423                 4
  IMS0725                                        No nicotinic acid     2                     0.434                 2
  IMS0726                                        No nicotinic acid     3                     0.441                 2
  IMS0730                                        No inositol           1                     0.392                 12
  IMS0731                                        No inositol           2                     0.389                 24
  IMS0732                                        No inositol           3                     0.399                 16
  IMS0727                                        No *p*ABA             1                     0.405                 6
  IMS0728                                        No *p*ABA             2                     0.389                 5
  IMS0729                                        No *p*ABA             3                     0.414                 4

![](AEM.00388-20-t0001)

ID, identifier.

Percentage improvement over the specific growth rate of the parental strain after three transfers in the same medium is also shown (*n* = 1 for each strain).

Whole-genome sequencing of evolved strains and target identification. {#s2.3}
---------------------------------------------------------------------

To identify mutations contributing to vitamin independence, the genomes of the sets of three independently evolved isolates for each SMDΔ version were sequenced with Illumina short-read technology. After aligning reads to the reference CEN.PK113-7D genome sequence ([@B23]), mapped data were analyzed for the presence of copy number variations (CNVs) and single nucleotide variations (SNVs) that occurred in annotated coding sequences.

A segmental amplification of 34 kb (from nucleotide 802500 to 837000) on chromosome VII, which harbors *THI4*, was observed in strain IMS0749 ([Fig. 4A](#F4){ref-type="fig"}), which had been evolved in SMDΔ lacking thiamine. *THI4* encodes a thiazole synthase, a suicide enzyme that can only perform a single catalytic turnover ([@B24]). Segmental amplifications on chromosomes III and VIII were observed in strain IMS0725, which had been evolved in SMDΔ lacking nicotinic acid ([Fig. 4B](#F4){ref-type="fig"}). Since these regions are known to be prone to recombination in the parental strain CEN.PK113-7D ([@B23], [@B25]), their amplification is not necessarily related to nicotinic acid independence.

![Read coverages across the chromosomes of evolved isolates IMS0725 evolved for nicotinic acid prototrophy (A) and IMS0749 evolved for thiamine prototrophy (B) (in red) compared to read coverage across the chromosomes of CEN.PK113-7D (in blue). Annotated genes found in the amplified region of IMS0749 are indicated.](AEM.00388-20-f0004){#F4}

SNV analysis was systematically performed, and data from the three sequenced isolates were compared. To eliminate false positives caused by mapping artifacts, reads of the CEN.PK113-7D strains were mapped back on its own reference assembly. Identified SNVs found were systematically subtracted. SNV analysis was restricted to non-synonymous mutations in coding sequences ([Table 2](#T2){ref-type="table"}).

###### 

Non-conservative mutations found in single-colony isolates obtained from serial transfer evolution experiments with S. cerevisiae CEN.PK113-7D on SMD variants lacking individual B vitamins[^*a*^](#T2F1){ref-type="table-fn"}

  Gene mutated in evolution expt   Codon change[^*b*^](#T2F2){ref-type="table-fn"}   Amino acid change   Gene annotation
  -------------------------------- ------------------------------------------------- ------------------- ----------------------------------------------------------------------------
  Pantothenate                                                                                           
      IMS0733                                                                                            
          *AMN1*                   agC-agG                                           S67R                Antagonist of mitotic exit network protein 1
          *DAN4*                   aTc-aCc                                           I353T               Cell wall protein, delayed anaerobic 4
          *ERG3*                   Gct-Cct                                           A145P               Delta(7)-sterol 5(6)-desaturase, ergosterol biosynthesis 3
          *ERR3*                   ttG-ttT                                           L344F               Enolase-related protein 3
  **  *ISW2***                     **tCa-tGa**                                       **S181Stop**        **ISWI chromatin-remodeling complex ATPase, imitation switch subfamily 2**
      IMS0734                                                                                            
          *CDC15*                  Aca-Gca                                           T262A               Cell division control protein 15
          *RPS14A*                 Cca-Tca                                           P94S                40S ribosomal protein S14-A
  **  *TUP1***                     **gTg-gCg**                                       **V374A**           **General transcriptional corepressor**
          *RRT6*                   gCg-gTg                                           A267V               Regulator of rRNA gene transcription protein 6
          *CEG1*                   gCa-gTa                                           A4V                 mRNA-capping enzyme subunit alpha
          *SCY1*                   Cct-Tct                                           P42S                Protein kinase-like protein SCY1
          *PDX1*                   gCa-gTa                                           A208V               Pyruvate dehydrogenase complex protein X component
          *TRM5*                   gCg-gTg                                           A106V               tRNA \[guanine(37)-N1\]-methyltransferase
          *GEF1*                   aGa-aTa                                           R637I               Anion/proton exchange transporter, glycerol ethanol, ferric requiring 1
          *LIP2*                   gGc-gAc                                           G235D               Octanoyltransferase
          *HFA1*                   Aag-Gag                                           K1021E              Acetyl coenzyme A carboxylase, mitochondrial
          *UBP8*                   aGt-aCt                                           S149T               Ubiquitin carboxyl-terminal hydrolase 8
          *MGS1*                   Cca-Aca                                           P392T               DNA-dependent ATPase
          *CPT1*                   Gtg-Atg                                           V255M               Cholinephosphotransferase 1
  **  *SPE2***                     **Gca-Aca**                                       **A278T**           ***S*-Adenosylmethionine decarboxylase proenzyme**
  **  *GAL11***                    **aTt-aAt**                                       **I541N**           **Mediator of RNA polymerase II transcription subunit 15**
          *CUE5*                   Cca-Tca                                           P377S               Ubiquitin-binding protein
          *MIP1*                   Gca-Aca                                           A630T               DNA polymerase gamma
          *POC4*                   aGc-aTc                                           S7I                 Proteasome chaperone 4
          *KAP120*                 tTg-tCg                                           L582S               Importin beta-like protein
          *KAP120*                 gAc-gGc                                           D850G               Importin beta-like protein
          *SEC16*                  Gca-Aca                                           A1015T              COPII coat assembly protein
      IMS0735                                                                                            
  **  *TUP1***                     **Cag-Tag**                                       **Q99Stop**         **General transcriptional corepressor**
  **  *FMS1***                     **Caa-Aaa**                                       **Q-33K**           **Polyamine oxidase**
  **  *GAL11***                    **Caa-Taa**                                       **Q383Stop**        **Mediator of RNA polymerase II transcription subunit 15**
  Pyridoxine                                                                                             
      IMS0736                                                                                            
  **  *BAS1***                     **cAa-cGa**                                       **Q152R**           **Myb-like DNA-binding protein, basal 1**
          *ERG5*                   Aga-Gga                                           R529G               C-22 sterol desaturase, ergosterol biosynthesis 5
      IMS0737                                                                                            
          *BAS1*                   Gat-Aat                                           D101N               Myb-like DNA-binding protein, basal 1
          *ERG5*                   Ggt-Tgt                                           G472C               C-22 sterol desaturase, ergosterol biosynthesis 5
      IMS0738                                                                                            
          *GIP4*                   Tcc-Ccc                                           S464P               GLC7-interacting protein 4
          *AOS1*                   Gtg-Atg                                           V286M               DNA damage tolerance protein RHC31
          *ORC4*                   aGt-aAt                                           S160N               Origin recognition complex subunit 4
          *MSB1*                   Att-Ttt                                           I180F               Morphogenesis-related protein, multicopy suppression of a budding defect 1
          *GCR2*                   Gga-Aga                                           G5R                 Glycolytic genes transcriptional activator, glycolysis regulation 2
          *VNX1*                   aCa-aTa                                           T490I               Low-affinity vacuolar monovalent cation/H^+^ antiporter
          *MMT1*                   gCt-gAt                                           A175D               Mitochondrial metal transporter 1
          *ISF1*                   Tat-Gat                                           Y220D               Increasing suppression factor 1
          *RPM2*                   Gcc-Acc                                           A1020T              Ribonuclease P protein component, mitochondrial
  **  *BAS1***                     **Tca-Cca**                                       **S41P**            **Myb-like DNA-binding protein, basal 1**
          *AAD14*                  agC-agA                                           S322R               Putative aryl-alcohol dehydrogenase AAD14
          *FAS1*                   gaA-gaT                                           E1829D              Fatty acid synthase subunit beta
          *BEM2*                   Aac-Cac                                           N792H               GTPase-activating protein, bud emergence 2/IPL2
          *APL1*                   gGt-gTt                                           G6V                 AP-2 complex subunit beta
          *DPB11*                  agG-agT                                           R699S               DNA replication regulator, DNA polymerase B (II) 11
          *LSB6*                   Aca-Gca                                           T458A               Phosphatidylinositol 4-kinase, las seventeen binding protein 6
          *EFG1*                   aAa-aGa                                           K188R               rRNA-processing protein, exit from G~1~ 1
          *CCH1*                   atG-atA                                           M828I               Calcium-channel protein 1
          *RNR4*                   Gca-Tca                                           A210S               Ribonucleoside-diphosphate reductase small chain 2
          *GCD2*                   tTa-tCa                                           L472S               Translation initiation factor eIF-2B subunit delta
          YHR219W                  aAt-aGt                                           N61S                Putative uncharacterized protein YHR219W
          *CDC37*                  Gcc-Tcc                                           A275S               Hsp90 cochaperone, cell division cycle 37
          *SRP101*                 Gca-Aca                                           A75T                Signal recognition particle receptor subunit alpha homolog
          *ADE8*                   Gca-Aca                                           A142T               Phosphoribosylglycinamide formyltransferase
          *AIM9*                   gCa-gTa                                           A23V                Altered inheritance of mitochondria protein 9, mitochondrial
          *UTP20*                  tAt-tGt                                           Y1492C              U3 small nucleolar RNA-associated protein 20
          *RIF1*                   aGc-aTc                                           S1516I              Telomere length regulator protein, RAP1-interacting factor 1
          *PHO87*                  Gtc-Atc                                           V482I               Inorganic phosphate transporter
          *MAK21*                  tTg-tCg                                           L413S               Ribosome biogenesis protein, maintenance of killer 21
          YDL176W                  tCa-tAa                                           S186-Stop           Uncharacterized protein YDL176W
  Thiamine                                                                                               
      IMS0747                                                                                            
          *MAL12*                  Gtt-Ctt                                           V305L               Alpha-glucosidase, maltose fermentation 12
  **  *CNB1***                     **ttA-ttT**                                       **L82F**            **Calcineurin subunit B**
          *PRP16*                  aAa-aGa                                           K112R               Pre-mRNA-splicing factor ATP-dependent RNA helicase
          *ERR3*                   ttG-ttT                                           L447F               Enolase-related protein 3
      IMS0748                                                                                            
  **  *PMR1***                     **tCc-tAc**                                       **S104Y**           **Calcium-transporting ATPase 1**
  **  *FRE2***                     **aCt-aGt**                                       **T110S**           **Ferric/cupric reductase transmembrane component 2**
      IMS0749                                                                                            
          YEL074W                  cAc-cCc                                           H66P                Putative UPF0320 protein YEL074W
  **  *CNB1***                     **ttA-ttC**                                       **L82F**            **Calcineurin subunit B**
          *MSC1*                   Gtt-Att                                           V309I               Meiotic sister chromatid recombination protein 1
          *ERR3*                   ttG-ttT                                           L447F               Enolase-related protein 3
  pABA                                                                                                   
      IMS0727                                                                                            
  **  *ABZ1***                     **cGt-cAt**                                       **R593H**           **Aminodeoxychorismate synthase**
      IMS0728                                                                                            
  **  *ARO7***                     **tTa-tCa**                                       **L205S**           **Chorismate mutase**
          *NUP57*                  tCc-tTc                                           S396F               Nucleoporin 57
      IMS0729                                                                                            
  **  *ABZ1***                     **cGt-cAt**                                       **R593H**           **Aminodeoxychorismate synthase**
          *HST2*                   ttG-ttT                                           L102F               NAD-dependent protein deacetylase, homolog of SIR two 2
  Inositol                                                                                               
      IMS0730                                                                                            
          YFR045W                  Gcc-Acc                                           A65T                Putative mitochondrial transport protein
      IMS0732                                                                                            
          YFR045W                  Gcc-Acc                                           A65T                Uncharacterized mitochondrial carrier
  Nicotinic acid                                                                                         
      IMS0724                                                                                            
          *RPG1*                   Ggt-Tgt                                           G294C               Eukaryotic translation initiation factor 3 subunit A
          *PMR1*                   Ggt-Agt                                           G694S               Calcium-transporting ATPase 1
      IMS0725                                                                                            
          *MTO1*                   atG-atT                                           M356I               Mitochondrial translation optimization protein 1
          *VTH2*                   Cca-Tca                                           P708S               Putative membrane glycoprotein, VPS10 homolog 2
          *VTH2*                   gTT-gCC                                           V478A               Putative membrane glycoprotein, VPS10 homolog 2
          *VTH2*                   TtT-GtG                                           F477V               Putative membrane glycoprotein, VPS10 homolog 2

![](AEM.00388-20-t0002)

Mutations that were chosen for subsequent reverse engineering experiments are shown in boldface font. S. cerevisiae strains IMS0731 and IMS0726 evolved for fast *myo*-inositol- and nicotinic acid-independent growth, respectively, did not reveal non-conservative mutations and were not included in the table.

Uppercase letters indicate the mutations.

In three of the six isolates from ALE experiments in SMDΔ lacking nicotinic acid or inositol, no non-synonymous SNVs were detected ([Fig. 5](#F5){ref-type="fig"}). One strain (IMS0724) from a serial transfer experiment on SMDΔ lacking nicotinic acid showed SNVs in *RPG1* and *PMR1*, while a second strain (IMS0725) showed SNVs in *MTO1* and *VTH2*. A mutation in YFR054W was identified in a single strain (IMS0730) evolved for inositol-independent growth. The absence of mutations in several strains subjected to serial transfer in SMDΔ lacking nicotinic acid or inositol is consistent with the fast growth of the parental strain CEN.PK113-7D in these media ([Fig. 2A](#F2){ref-type="fig"}).

![Venn diagrams showing non-synonymous mutations found in coding regions of isolated strains from the different evolution experiments. Each evolution experiment was performed in triplicates. The Venn diagrams show genes that acquired non-synonymous mutations in multiple independent evolution experiments for a specific medium as well as genes that were affected in a single replicate. Apparent mutations also found in the genome of the parent strain CEN.PK113-7D were subtracted and not shown. Target genes that were selected for reverse engineering are shown in red.](AEM.00388-20-f0005){#F5}

Sequencing of the three isolates evolved in SMDΔ lacking *p*ABA revealed only five SNVs, of which two were in *ABZ1* (strains IMS0727 and IMS0729) and one in *ARO7* (IMS0728), while SNVs in *NUP57* and *HTS2* were found in strains IMS0728 and IMS0729, respectively ([Fig. 5](#F5){ref-type="fig"}). *NUP57* and *HTS2* could not be directly linked to *p*ABA metabolism. Conversely, Abz1 is an aminodeoxychorismate synthase that directs chorismate toward *p*ABA synthesis, and Aro7 is a chorismate mutase that catalyzes the first committed reaction toward phenylalanine and tyrosine and thereby diverts chorismate from *p*ABA synthesis ([Fig. 1](#F1){ref-type="fig"}) ([@B26], [@B27]). These two SNVs therefore represented clear targets for reverse engineering ([Table 2](#T2){ref-type="table"}).

In line with the much longer ALE experiments (approximately 332 generations), strains evolved in SMDΔ lacking thiamine, pantothenate, or pyridoxine showed larger numbers of SNVs, with a maximum number of 30 SNVs in the isolate IMS0738 evolved in SMDΔ lacking pyridoxine ([Table 2](#T2){ref-type="table"} and [Fig. 5](#F5){ref-type="fig"}).

Evolution on SMDΔ lacking thiamine did not yield mutations that affected the same gene in all three independently evolved isolates. However, strains IMS0747 and IMS0749 shared SNVs in *CNB1* and *ERR3*. A third isolate, strain IMS0748, contained two SNVs in *PMR1* and *FRE2. CNB1*, *PMR1*, and *FRE2* all encode proteins that have been implicated in divalent cation homeostasis ([@B28][@B29][@B32]).

Isolates IMS0736 and IMS0737, which had been evolved in SMDΔ lacking pyridoxine, harbored only two and three mutations, respectively, while strain IMS0738 harbored 30 mutations. All three strains carried different mutated alleles of *BAS1*, which encodes a transcription factor involved in regulation of histidine and purine biosynthesis ([@B33], [@B34]). IMS0736 harbored a non-synonymous mutation causing an amino acid change position 152 (Q152R), while SNVs in strains IMS0737 and IMS0738 affected amino acids 101 (D101N) and 41 (S41P), respectively. Based on these results, *BAS1* was identified as priority target for reverse engineering.

Isolates IMS0733 and IMS0735, evolved on SMDΔ lacking pantothenic acid, carried three and five SNVs, respectively, while isolate IMS0734 carried 21 mutations. Isolates IMS0734 and IMS0735 both carried mutations in *TUP1* and *GAL11*, resulting in different single-amino acid changes (Tup1^V374A^ Gal11^I541N^ and Tup1^Q99stop^ Gal11^Q383stop^, respectively). *TUP1* codes for a general transcriptional corepressor ([@B35]), while *GAL11* codes for a subunit of the tail of the mediator complex that regulates activity of RNA polymerase II ([@B36]). One of the mutations in strain IMS0733 affected *ISW2*, which encodes a subunit of the chromatin remodeling complex ([@B37]). These three genes involved in regulatory processes were selected for reverse engineering, along with *SPE2* and *FMS1*. The latter two genes, encoding *S*-adenosylmethionine decarboxylase ([@B38]) and polyamine oxidase ([@B39]), are directly involved in pantothenate biosynthesis and were found to be mutated in isolates IMS0734 and IMS0735, respectively.

In summary, based on mutations in the same gene in independently evolved isolates and/or existing information on involvement of affected genes in vitamin biosynthesis, mutations in 12 genes were selected for reconstruction in the parental strain CEN.PK113-7D. These were mutated alleles of *ISW2*, *GAL11*, *TUP1*, *FMS1*, and *SPE2* for pantothenate, in *BAS1* for pyridoxine, mutations in *CNB1*, *PMR1*, and *FRE2* as well as overexpression of *THI4* for thiamine, and mutations in *ABZ1* and *ARO7* for pABA. Since serial transfer on SMDΔ lacking nicotinic acid or inositol did not consistently yield mutations and the parental strain CEN.PK113-7D already grew fast on these media, no reverse engineering of mutations observed in isolates from those experiments was carried out.

Reverse engineering of target gene mutations and overexpression. {#s2.4}
----------------------------------------------------------------

To investigate whether the selected targets contributed to the phenotypes of the evolved strains, single point mutations or single-gene overexpression cassettes were introduced in a non-evolved reference strain, followed by analysis of specific growth rate in the relevant SMDΔ variant. For most target genes, a two-step strategy was adopted, so that a single-gene knockout mutant was constructed in the process ([Fig. 6A](#F6){ref-type="fig"} and [B](#F6){ref-type="fig"}). For the *SPE2* mutant strains IMX2308 and IMX2289, point mutations were introduced in a single step ([Fig. 6C](#F6){ref-type="fig"}). The *THI4*-overexpressing strains IMX2290 and IMX2291 were constructed by integrating the overexpression cassette at the YPRcTau3 locus ([@B40]) ([Fig. 6D](#F6){ref-type="fig"}). Subsequently, multiple mutations that were found in strains evolved in the same SMDΔ version were combined into single engineered strains to test for additive or synergistic effects.

![Strain construction strategies for reverse engineering. Most of the single mutation strains were generated in two steps. (A) First the gene of interest (GOI) was replaced by a synthetic 20-bp target sequence and 3-bp PAM sequence (SynPAM). In a second step, the SynPAM was targeted by Cas9 and substituted with the GOI mutant allele. (B) The SynPAM approach was not successful in targeting *BAS1*. For this reason, the *BAS1* mutant strains (IMX2135 to 2137) were constructed by first knocking out the gene by replacing it with the antibiotic marker hphNT1 that confers resistance to hygromycin. Then, in a second step, the selection marker was targeted with Cas9 and substituted with a *BAS1* mutant allele. (C) In the case of *SPE2* mutant strains (IMX2289 and IMX2308), the mutant allele was swapped with the wild-type (WT) allele in a single step. (D) The *THI4* overexpressing strains IMX2290 and IMX2291 were constructed by integrating a *THI4* overexpression cassette at the YPRcTau3 locus. SNVs are represented by yellow boxes.](AEM.00388-20-f0006){#F6}

Thiamine. {#s2.5}
---------

The specific growth rate of S. cerevisiae CEN.PK113-7D was only 27% lower in SMDΔ lacking thiamine than in complete SMD ([Fig. 2A](#F2){ref-type="fig"}). Nevertheless, it took more than 300 generations of selective growth to obtain evolved isolates that compensated for this difference ([Fig. 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). The role of mutations in *CNB1*, *FRE2*, and *PMR1* in this evolved phenotype was first investigated in the single knockout strains IMX1721, IMX1722, and IMX1723, respectively. While deletion of *PMR1* negatively affected the specific growth rate on SMDΔ lacking thiamine, deletion of either *CNB1* or *FRE2* resulted in a 17% increase of the specific growth rate on this medium relative to that of CEN.PK113-7D. However, strains IMX1721 (*cnb1*Δ) and IMX1722 (*fre2*Δ) still grew significantly slower than the evolved isolates ([Fig. 7](#F7){ref-type="fig"}). Subsequently, the mutated alleles found in the evolved isolates were introduced at the native chromosomal locus, resulting in strains IMX1985 (*CNB1*^L82F^), IMX1986 (*PMR1*^S104Y^), and IMX1987 (*FRE2*^T110S^). In addition, *THI4* was overexpressed (strain IMX2290) to simulate the copy number increase observed in IMS0749. Strains IMX1987 (*FRE2*^T110S^) and IMX2290 (*THI4*↑) grew as fast as the evolved isolates on SMDΔ lacking thiamine (0.35 to 0.36 h^−1^) ([Fig. 7](#F7){ref-type="fig"}). Combination of these mutated alleles of *PMR1* and *FRE2*, which occurred together in isolate IMS0748, as well as of the two mutations resulting in growth improvement (*FRE2*^T110S^ and *THI4*↑) was also tested. None of these combinations yielded a higher specific growth rate than observed in the evolved strains and in the reverse-engineered *FRE2*^T110S^ and *THI4*↑ strains.

![Specific growth rates of engineered *S. cerevisiae* strains carrying one or multiple gene deletions or reverse-engineered mutations in SMD media lacking thiamine (top), *p*ABA (second from top), pantothenic acid (middle), and pyridoxine (bottom). Specific growth rates of *S. cerevisiae* CEN.PK113-7D grown in complete SMD and evolved CEN.PK113-7D in SMD medium lacking the relevant vitamin are shown as references. The specific growth rate of strain CEN.PK113-7D in SMD medium lacking the relevant vitamin is shown and highlighted by a vertical line to help to visualize improved performance of engineered strains. Error bars represent the standard deviations (*n* = 9 for complete SMD, *n* = 6 for strain IMX1721; otherwise *n* = 3). A Student's *t* test was performed to compare the wild-type and evolved CEN.PK113-7D growth rate to the engineered strain growth rates, and non-significant differences are indicated with white letters (*P* value \> 0.05).](AEM.00388-20-f0007){#F7}

*para*-Aminobenzoic acid. {#s2.6}
-------------------------

In SMDΔ lacking *p*ABA, strain CEN.PK113-7D grew 50% slower than in complete SMD. However, it took only a few transfers to achieve fast *p*ABA-independent growth. The independently evolved isolates IMX2057 and IMX1989 harbored mutations affecting genes that encode chorismate-utilizing enzymes, the precursor of *p*ABA (*ABZ1*^N593H^ and *ARO7*^L205S^, respectively) ([Fig. 1](#F1){ref-type="fig"}). As these strains were able to grow in SMD without amino acid supplementation, these mutations did not cause a complete loss of function. However, they might well have affected the distribution of chorismate over *p*ABA and aromatic amino acid biosynthesis ([@B26], [@B27]). Introduction of either *ABZ1*^N593H^ or *ARO7*^L205S^, while replacing the corresponding wild-type allele, eliminated the slower growth observed in strain CEN.PK113-7D during the first transfer on SMDΔ lacking *p*ABA. Specific growth rates of these reverse-engineered strains IMX2057 (*ABZ1*^R593H^) and IMX1989 (*ARO7*^L205S^) were not statistically different from those of the corresponding evolved isolates ([Fig. 7](#F7){ref-type="fig"}).

Pantothenic acid. {#s2.7}
-----------------

Omission of pantothenic acid from SMD led to a 57% lower specific growth rate of strain CEN.PK113-7D than observed in complete SMD ([Fig. 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Of a total number of 29 mutations found in three independently evolved isolates that showed fast growth in SMDΔ lacking pantothenate, SNVs in *ISW2*, *GAL11*, *TUP1*, *SPE2*, and *FMS1* were analyzed by reverse engineering. Single deletions of *SPE2*, *FMS1*, and *GAL11* resulted in an inability to grow on SMDΔ lacking pantothenate. This result was anticipated for the *spe2*Δ and *fms1*Δ mutants, in view of the roles of these genes in pantothenate biosynthesis. However, *GAL11* was not previously implicated in pantothenate biosynthesis. The *gal11*Δ strain was conditional, as the mutant did grow on complex yeast extract-peptone-dextrose (YPD) and SMD media. Of the remaining two deletion mutants, the *tup1*Δ strain IMX1817 showed a 68% higher specific growth rate on SMDΔ than strain CEN.PK113-7D, while deletion of *ISW2* did not result in faster growth on this medium ([Fig. 7](#F7){ref-type="fig"}). Of seven SNVs that were individually expressed in the non-evolved strain background, only the *GAL11*^Q383stop^ mutation found in IMS0735 supported a specific growth rate of 0.33 h^−1^ on SMDΔ lacking pantothenate that was only 8% lower than that of the evolved isolates.

Combination of the *GAL11*^Q383stop^ mutation with *TUP1*^Q99stop^, and *TUP1* with *FMS1*, did not lead to additional improvement, indicating that the *GAL11*^Q383stop^ mutation was predominantly responsible for the improved growth of evolved strain IMS0735 in the absence of pantothenate.

Pyridoxine. {#s2.8}
-----------

Strain CEN.PK113-7D grew 35% slower on SMDΔ lacking pyridoxine than on complete SMD ([Fig. 2](#F2){ref-type="fig"}). Three different mutated alleles of *BAS1* were identified in strains that had been independently evolved for fast growth on the former medium ([Fig. 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Deletion, in a non-evolved reference strain, of *BAS1* (IMX2128) did not result in faster pyridoxine-independent growth ([Fig. 7](#F7){ref-type="fig"}). Individual expression of the evolved *BAS1* alleles in strain IMX2128 yielded strains IMX2135 (*BAS1*^Q152R^), IMX2136 (*BAS1*^D101N^), and IMX2137 (*BAS1*^S41P^). All three *BAS1* mutant strains grew faster on SMDΔ lacking pyridoxine than strain CEN.PK113-7D, reaching specific growth rates on this medium that were not significantly different from the average of those of evolved strains IMS736, IMS737, and IMS738 ([Fig. 7](#F7){ref-type="fig"}). These results suggest that *BAS1*, which was previously shown to be involved in regulation of purine and histidine biosynthesis ([@B33], [@B34]), may also be involved in regulation of pyridoxine biosynthesis in S. cerevisiae.

DISCUSSION {#s3}
==========

Vitamin requirements of S. cerevisiae. {#s3.1}
--------------------------------------

Most S. cerevisiae genomes harbor the full complement of genes required for synthesis of the seven B vitamins that are commonly included in chemically defined media for yeast cultivation (CDMY; for a recent review see references [@B5] and [@B10]). Previous studies indicated that the presence of a complete set of biotin biosynthesis genes supported only slow growth on CDMY. The present study shows that, similarly, none of the other six B vitamins included in CDMY (inositol, nicotinic acid, pantothenic acid, *p*ABA, pyridoxine, and thiamine) are strictly required for growth. Remarkably, the impact of individually eliminating these six vitamins from glucose-containing CDMY differently affected specific growth rates in aerobic glucose-grown cultures, with growth rate reductions varying from 0% to 57%. It should, however, be noted that requirements for these growth factors, which for aerobic yeast cultivation cannot be formally defined as vitamins, and their absolute and relative requirements may well be condition and strain dependent. For example, it is well documented that synthesis of nicotinic acid and pantothenic acid by S. cerevisiae is strictly oxygen dependent ([@B41]). The data set compiled in the present study will, hopefully, serve as reference for investigating vitamin requirements of diverse natural isolates and laboratory and industrial strains and thereby help to obtain a deeper understanding of the genetics and ecology of vitamin prototrophy and vitamin biosynthesis in S. cerevisiae.

ALE and reverse engineering for identifying genes involved in fast B vitamin-independent growth. {#s3.2}
------------------------------------------------------------------------------------------------

A serial transfer strategy was applied to select for spontaneous mutants that grew as fast in aerobic batch cultures on CDMY lacking either inositol, nicotinic acid, pyridoxine, thiamine, pantothenic acid, or *para*-aminobenzoic acid as in CDMY containing all these six vitamins as well as biotin. In the ALE experiments on media lacking nicotinic acid or inositol, fast growth was observed within a few cycles of batch cultivation, and not all fast-growing strains were found to contain mutations. These observations indicated that, under the experimental conditions, the native metabolic and regulatory network of S. cerevisiae was able to meet cellular requirements for fast growth in the absence of these "vitamins."

As demonstrated in other ALE studies, performing independent replicate evolution experiments helped in identifying biologically relevant mutations upon subsequent whole-genome sequencing ([@B11], [@B12]). The power of this approach is illustrated by the ALE experiments that selected for pyridoxine-independent growth, in which the independently evolved mutants IMS0736 and IMS0738 harbored 2 and 30 mutated genes, respectively, of which only *BAS1* also carried a mutation in a third independently sequenced isolate ([Fig. 5](#F5){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

In total, the role of 12 genes that were found to be mutated in the ALE experiments were selected for further analysis by reverse engineering of the evolved alleles and/or deletion mutations in the parental non-evolved genetic background ([Fig. 5](#F5){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). These genes comprised three groups: (i) genes encoding enzymes known or inferred to be involved in the relevant vitamin synthesis pathway (*SPE2* and *FMS1* for pantothenate, *THI4* for thiamine, and *ABZ1* and *ARO7* for *p*ABA), (ii) genes encoding transcriptional regulator proteins (*TUP1* and *GAL11* for pantothenate and *BAS1* for pyridoxine), and (iii) non-transcriptional-regulator proteins whose functions were not previously associated with vitamin biosynthesis (*ISW2* for pantothenate and *CNB1*, *PMR1*, and *FRE2* for thiamine).

Of the first group of mutations defined above, only those in *SPE2* and *FMS1* were not found to contribute to faster growth in the absence of the relevant vitamin. The second group yielded interesting information on the regulation of vitamin biosynthesis in S. cerevisiae. In particular, the key role of mutations in *BAS1* in enabling fast pyridoxine-independent growth and the role of *GAL11* and *TUP1* mutations in fast pantothenate-independent growth dependency provided interesting insights and leads for further research.

The S. cerevisiae transcriptional activator Bas1 is involved in the regulation of purine and histidine ([@B33], [@B34]). Interestingly, Bas1 is also involved in the repression of genes involved in C~1~ metabolism and of *SNZ1* ([@B42]). Snz1 is a subunit of a two-component pyridoxal-5′-phosphate synthase, which catalyzes the first step of the synthesis of pyridoxal-5-phosphate, the active form of pyridoxine in S. cerevisiae ([@B43]). Interrogation of the Yeastract database ([@B44]) for occurrence of transcription binding sites in promoter regions of pyridoxine biosynthesis genes confirmed the link already established between *BAS1* and *SNZ1* ([@B42], [@B45]). Moreover, this analysis revealed that all pyridoxine biosynthesis genes in S. cerevisiae contain a consensus Bas1 *cis*-regulatory binding motif ([Fig. 8](#F8){ref-type="fig"}). Consistent with the regulatory role of Bas1 on *SNZ1* expression, Bas1 has been experimentally shown to repress transcription of genes involved in pyridoxine biosynthesis ([@B46]). The mutations found in *BAS1* may, therefore, have attenuated Bas1-mediated repression of pyridoxine biosynthetic genes and, thereby, enabled increased pyridoxine biosynthesis.

![Schematic representation of Bas1 binding sites in promoter regions of genes involved in pyridoxal-5-phosphate biosynthesis. The two Bas1 consensus binding sequences MAMaGAGT and kTGAGAkA ([@B75]) are shown in green and blue, respectively.](AEM.00388-20-f0008){#F8}

ALE experiments in pantothenate-free medium yielded different mutations in *TUP1* and *GAL11*, two major components of the yeast regulatory machinery. *TUP1* encodes a general transcriptional repressor that, in a complex with Cyc8, modifies chromatin structure such that genes are repressed ([@B47][@B48][@B49]). *GAL11* (also known as *MED15*) encodes a subunit of the mediator complex required for initiation by RNA polymerase II and consequently plays a critical role in transcription of a large number of RNA polymerase II-dependent genes ([@B50], [@B51]). Despite its involvement in general cellular transcriptional regulation, *GAL11* is not an essential gene for growth in complete medium ([@B52]). The inability of a *gal11*Δ strain to grow on glucose synthetic medium without pantothenate represents the first indication for a possible involvement of Gal11 in regulation of pantothenate metabolism. Gal11 interacts with transcriptional activators through various peptidic segments, including an N-terminal KIX domain. This region shows homology with the B-box motif found in the mammalian activating protein SRC-1 and is essential for recruitment of the mediator complex by other regulatory proteins (e.g., Gcn4) ([@B53]). Of two mutations found in *GAL11*, the most potent was a nonsense mutation at nucleotide 383. In contrast to a *gal11*Δ strain, a reverse-engineered strain carrying this premature stop codon grew on SMDΔ pantothenate, which indicates that the *GAL11*^Q383stop^ allele encodes a functional peptide. Such a functional truncated Gal11 version was not previously described and is sufficiently long to include a complete KIX domain (AA~9~ to AA~86~) for recruitment of the RNA polymerase II machinery by an as yet unidentified transcription factor involved in regulation of pantothenate biosynthesis. Further research is required to resolve and understand the role of the wild-type and evolved alleles of *GAL11* in regulation of pantothenate metabolism.

A third group of non-transcription factor genes had not yet been associated with the biosynthesis of vitamins. Reverse engineering of a mutation in *ISW2*, which encodes an ATP-dependent DNA translocase involved in chromatin remodeling ([@B54]) identified in the pantothenate evolution, did not yield a growth improvement. We cannot exclude that this mutation in association with *ERG3*, *AMN1*, *DAN4*, and *ERR3* identified in IMS0733 ([Fig. 5](#F5){ref-type="fig"} and [Table 2](#T2){ref-type="table"}) might have a significant impact, but systematic combinatorial analysis of the mutations was not performed.

Mutations in *CNB1*, *PMR1*, and *FRE2* identified in evolved isolates all improved growth of S. cerevisiae in the absence of thiamine ([Fig. 7](#F7){ref-type="fig"}, top). These three genes all encode proteins involved in metal homeostasis: Fre2 is a ferric or cupric reductase ([@B55]), and Cnb1 is the regulatory B subunit of calcineurin, a Ca^2+^/calmodulin-regulated type 2B protein phosphatase which regulates the nuclear localization of Crz1. This transcription factor influences the expression of a large number of genes. Its targets include *PMR1*, which encodes a high-affinity Ca^2+^/Mn^2+^ P-type ATPase involved in Ca^2+^ and Mn^2+^ transport into the Golgi apparaus ([@B30], [@B56]). Neither of these three genes has hitherto been directly associated with thiamine. However, thiamine pyrophosphokinase (Thi80), thiamine phosphate synthase (Thi6), and hydroxymethylpyrimidine phosphate (Thi21 and Thi20) all require Mg^2+^ or Mn^2+^ as cofactors ([@B57], [@B58]). At low concentration, Mn^2+^ was shown to be a stronger activator of Thi80 than Mg^2+^([@B59]). In an ALE experiment with engineered xylose-fermenting assimilating S. cerevisiae, a nonsense mutation or deletion of *PMR1* caused selectively and strongly increased intracellular concentrations of Mn^2+^, which was the preferred metal ion for the heterologously expressed *Piromyces* xylose isomerase ([@B60]). Although intracellular metal ion concentrations were not measured in the present study, the different phenotypes of a *pmr1*Δ deletion strain (IMX1722) and a *PMR1*^S104Y^ strain (IMX1986) ([Fig. 7](#F7){ref-type="fig"}, top) indicate that the latter mutation does not act through a massive increase of the intracellular Mn^2+^ concentration.

In S. cerevisiae, synthesis of the thiazole moiety of thiamine biosynthesis involves sulfide transfer from an active-site cysteine (Cys205) residue of the thiazole synthase Thi4. This sulfur transfer reaction is iron dependent and generates inactive enzyme by formation of a dehydroalanine. Fe(II) plays an essential role in this sulfide transfer, which remains poorly understood ([@B24]). Further research is needed to investigate if the *FRE2* mutation in strain IMS0749 in some way increases the efficiency of the reaction catalyzed by the energetic single-turnover enzyme Thi4 and to resolve the role of metal homeostasis in vitamin biosynthesis.

Towards mineral media for cultivation of S. cerevisiae. {#s3.3}
-------------------------------------------------------

With the exception of the carbon and energy sources for growth, B vitamins are the sole organic ingredients in standard CDMY recipes for aerobic cultivation of wild-type and industrial S. cerevisiae strains. In view of the chemical instability of some of these compounds, vitamin solutions cannot be autoclaved along with other medium components but are usually filter sterilized. In research laboratories and, in particular, in industrial processes, the costs, complexity, and contamination risks associated with the use of vitamins is significant. Complete elimination of vitamins from CDMY, without compromising specific growth rate, yield, or productivity, could therefore result in considerable cost and time savings as well as in improved standardization and robustness of cultivation procedures.

The present study demonstrates that, by ALE as well as introduction of small sets of defined mutations into S. cerevisiae, it is possible to achieve specific growth rates in single-vitamin-depleted CDMY that are close or identical to those found in CDMY supplemented with a complete vitamin mixture. While these results represent a first step toward the construction of prototrophic growth of S. cerevisiae and related yeasts, further research is required which trade-offs are incurred upon simultaneous introduction of the genetic interventions identified in this study and how they can be mitigated. This issue may be particularly relevant for mutations that affect genes involved in global regulation processes ([@B51], [@B61]), which may interfere with other cellular processes. In addition, simultaneous high-level expression of multiple enzymes with low-catalytic turnover numbers, with the suicide enzyme Thi4 ([@B24], [@B62], [@B63]) as an extreme example, may affect cell physiology due to the required resource allocation ([@B64], [@B65]).

In such cases, it may be necessary to expand metabolic engineering strategies beyond the native metabolic and regulatory capabilities of S. cerevisiae by expression of heterologous proteins and/or pathways with more favorable characteristics ([@B66]).

MATERIALS AND METHODS {#s4}
=====================

Strains, media, and maintenance. {#s4.1}
--------------------------------

The S. cerevisiae strains used and constructed in this study are shown in [Table 3](#T3){ref-type="table"} and they all derive from the CEN.PK lineage ([@B17], [@B67]). Yeast strains were grown on synthetic medium with ammonium sulfate as a nitrogen source (SM) or YP medium (10 g/liter Bacto yeast extract, 20 g/liter Bacto peptone) as previously described ([@B2]). SM and YP media were autoclaved at 121°C for 20 min. Then, SM medium was supplemented with 1 ml/liter of filter-sterilized vitamin solution \[0.05 g/liter [d]{.smallcaps}-(+)-biotin, 1.0 g/liter [d]{.smallcaps}-calcium pantothenate, 1.0 g/liter nicotinic acid, 25 g/liter *myo*-inositol, 1.0 g/liter thiamine hydrochloride, 1.0 g/liter pyridoxol hydrochloride, 0.20 g/liter 4-aminobenzoic acid\]. Vitamin dropout media were prepared using vitamin solutions lacking either thiamine, pyridoxine, pantothenic acid, inositol, nicotinic acid, or *para*-aminobenzoic acid, yielding SMΔthiamine, SMΔpyridoxine, SMΔpantothenic acid, SMΔinositol, SMΔnicotinic acid, and SMΔ*p*ABA, respectively. A concentrated glucose solution was autoclaved at 110°C for 20 min and then added to the SM and YP media at a final concentration of 20 g/liter, yielding SMD and YPD, respectively. Five hundred-milliliter shake flasks containing 100 ml medium and 100-ml shake flasks containing 20 ml medium were incubated at 30°C and at 200 rpm in an Innova incubator (Brunswick Scientific, Edison, NJ). Solid media were prepared by adding 1.5% Bacto agar and, when indicated, 200 mg/liter G418 or 200 mg/liter hygromycin. Escherichia coli strains were grown in LB (10 g/liter Bacto tryptone, 5 g/liter Bacto yeast extract, 5 g/liter NaCl) supplemented with 100 mg/liter ampicillin or kanamycin. S. cerevisiae and E. coli cultures were stored at −80°C after the addition of 30% (vol/vol) glycerol.

###### 

Saccharomyces cerevisiae strains used in this study

  Strain ID      Relevant genotype or characteristic                                                                      Parental strain   Reference
  -------------- -------------------------------------------------------------------------------------------------------- ----------------- ------------
  CEN.PK113-7D   *MAT***a**                                                                                                                 [@B17]
  CEN.PK113-5D   *MAT***a** *ura3-52*                                                                                                       [@B17]
  IMX585         *MAT***a** *can1*Δ::*cas9*-natNT2 U                                                                      CEN.PK113-7D      [@B73]
  IMS0721        *MAT***a** evolved in SMD colony 1                                                                       CEN.PK113-7D      This study
  IMS0722        *MAT***a** evolved in SMD colony 2                                                                       CEN.PK113-7D      This study
  IMS0723        *MAT***a** evolved in SMD colony 3                                                                       CEN.PK113-7D      This study
  IMS0724        *MAT***a** evolved in Δnicotinic acidSMD colony 1                                                        CEN.PK113-7D      This study
  IMS0725        *MAT***a** evolved in Δnicotinic acidSMD colony 2                                                        CEN.PK113-7D      This study
  IMS0726        *MAT***a** evolved in Δnicotinic acidSMD colony 3                                                        CEN.PK113-7D      This study
  IMS0727        *MAT***a** evolved in ΔpabaSMD colony 1                                                                  CEN.PK113-7D      This study
  IMS0728        *MAT***a** evolved in ΔpabaSMD colony 2                                                                  CEN.PK113-7D      This study
  IMS0729        *MAT***a** evolved in ΔpabaSMD colony 3                                                                  CEN.PK113-7D      This study
  IMS0730        *MAT***a** evolved in ΔinositolSMD colony 1                                                              CEN.PK113-7D      This study
  IMS0731        Demonstrate evolved in ΔinositolSMD colony 2                                                             CEN.PK113-7D      This study
  IMS0732        *MAT***a** evolved in ΔinositolSMD colony 3                                                              CEN.PK113-7D      This study
  IMS0733        *MAT***a** evolved in Δpantothenic acidSMD colony 1                                                      CEN.PK113-7D      This study
  IMS0734        *MAT***a** evolved in Δpantothenic acidSMD colony 2                                                      CEN.PK113-7D      This study
  IMS0735        *MAT***a** evolved in Δpantothenic acidSMD colony 3                                                      CEN.PK113-7D      This study
  IMS0736        *MAT***a** evolved in ΔpyridoxineSMD colony 1                                                            CEN.PK113-7D      This study
  IMS0737        *MAT***a** evolved in ΔpyridoxineSMD colony 2                                                            CEN.PK113-7D      This study
  IMS0738        *MAT***a** evolved in ΔpyridoxineSMD colony 3                                                            CEN.PK113-7D      This study
  IMS0747        *MAT***a** evolved in ΔthiamineSMD colony 1                                                              CEN.PK113-7D      This study
  IMS0748        *MAT***a** evolved in ΔthiamineSMD colony 2                                                              CEN.PK113-7D      This study
  IMS0749        *MAT***a** evolved in ΔthiamineSMD colony 3                                                              CEN.PK113-7D      This study
  IMX1721        *MAT***a** *can1*Δ::*cas9*-natNT2 *cnb1*Δ::SynPAM                                                        IMX585            This study
  IMX1722        *MAT***a** *can1*Δ::*cas9*-natNT2 *pmr1*Δ::SynPAM                                                        IMX585            This study
  IMX1723        *MAT***a** *can1*Δ::*cas9*-natNT2 *fre2*Δ::SynPAM                                                        IMX585            This study
  IMX1817        *MAT***a** *can1*Δ::*cas9*-natNT2 *tup1*Δ::SynPAM                                                        IMX585            This study
  IMX1818        *MAT***a** *can1*Δ::*cas9*-natNT2 *isw2*Δ::SynPAM                                                        IMX585            This study
  IMX1819        *MAT***a** *can1*Δ::*cas9*-natNT2 *gal11*Δ::SynPAM                                                       IMX585            This study
  IMX1920        *MAT***a** *can1*Δ::*cas9*-natNT2 *aro7*Δ::SynPAM                                                        IMX585            This study
  IMX1985        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*CNB1*^L82F^                                                  IMX1721           This study
  IMX1986        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*PMR1*^S104Y^                                                 IMX1722           This study
  IMX1987        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*FRE2*^T110S^                                                 IMX1723           This study
  IMX1988        *MAT***a** *can1*Δ::*cas9*-natNT2 *abz1*Δ::SynPAM                                                        IMX585            This study
  IMX1989        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*ARO7*^L205S^                                                 IMX1920           This study
  IMX1990        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*ISW2*^S181stop^                                              IMX1818           This study
  IMX1991        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*GAL11*^I541N^                                                IMX1819           This study
  IMX1992        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*GAL11*^Q383stop^                                             IMX1819           This study
  IMX2002        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*TUP1*^V374A^                                                 IMX1817           This study
  IMX2003        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*TUP1*^Q99stop^                                               IMX1817           This study
  IMX2043        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*FRE2*^T110S^ *pmr1*Δ::*PMR1*^S104Y^                          IMX1986           This study
  IMX2057        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*ABZ1*^R593H^                                                 IMX1988           This study
  IMX2066        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*TUP1*^V374A^ *gal11*Δ::SynPAM                                IMX2002           This study
  IMX2110        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*GAL11*^Q383stop^ *tup1*Δ::SynPAM                             IMX1992           This study
  IMX2127        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*GAL11*^Q383stop^ SynPAMΔ::*TUP1*^Q99stop^                    IMX2110           This study
  IMX2128        *MAT***a** *can1*Δ::*cas9*-natNT2 *bas1*Δ::hphNT1                                                        IMX585            This study
  IMX2087        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*TUP1*^V374A^ SynPAMΔ::*GAL11*^I541N^                         IMX2066           This study
  IMX2135        *MAT***a** *can1*Δ::*cas9*-natNT2 hphNT1Δ::*BAS1^Q152R^*                                                 IMX2128           This study
  IMX2136        *MAT***a** *can1*Δ::*cas9*-natNT2 hphNT1Δ::*BAS1*^D101N^                                                 IMX2128           This study
  IMX2137        *MAT***a** *can1*Δ::*cas9*-natNT2 hphNT1Δ::*BAS1*^S41P^                                                  IMX2128           This study
  IMX2290        *MAT***a** *can1*Δ::*cas9*-natNT2 YPRcTau3::*pTDH3-THI4-tTDH1*                                           IMX585            This study
  IMX2291        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*CNB1*^L82F^ YPRcTau3::*pTDH3-THI4-tTDH*1                     IMX1985           This study
  IMX2289        M*MAT***a** ATa *can1*Δ::*cas9*-natNT2 *SPE2*^A278T^                                                     IMX585            This study
  IMX2292        *MAT***a** *can1*Δ::*cas9*-natNT2 *fms1*Δ::SynPAM                                                        IMX585            This study
  IMX2306        M*MAT***a** ATa *can1*Δ::*cas9*-natNT2 SynPAMΔ::*FMS1*^Q33K^                                             IMX2292           This study
  IMX2308        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*GAL11*^Q383stop^ SynPAMΔ::*TUP1*^V374A^ *SPE2*^A278T^        IMX2127           This study
  IMX2294        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*TUP1*^V374A^ SynPAMΔ::*GAL11*^I541N^ *FMS1*^Q33K^::SynPAM    IMX2087           This study
  IMX2307        *MAT***a** *can1*Δ::*cas9*-natNT2 SynPAMΔ::*TUP1*^V374A^ SynPAMΔ::*GAL11*^I541N^ SynPAMΔ::*FMS1*^Q33K^   IMX2294           This study
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Molecular biology techniques. {#s4.2}
-----------------------------

PCR amplification of DNA fragments with Phusion Hot Start II high-fidelity polymerase (Thermo Scientific, Waltham, MA) and desalted or PAGE-purified oligonucleotide primers (Sigma-Aldrich, St. Louis, MO) was performed according to the manufacturers' instructions. DreamTaq polymerase (Thermo Scientific) was used for diagnostic PCR. Primers used in this study are shown in [Table 4](#T4){ref-type="table"}. PCR products were separated by gel electrophoresis using 1% (wt/vol) agarose gels (Thermo Scientific) in Tris-acetate-EDTA (TAE) buffer (Thermo Scientific) at 100 V for 25 min and purified either with a GenElutePCR Clean-Up kit (Sigma-Aldrich) or with a Zymoclean Gel DNA Recovery kit (Zymo Research, Irvine, CA). Plasmids were purified from E. coli using a Sigma GenElute Plasmid kit (Sigma-Aldrich). Plasmids used in this study are shown in [Table 5](#T5){ref-type="table"}. Yeast genomic DNA was isolated with the SDS-lithium acetate (LiAc) protocol ([@B68]). Yeast strains were transformed with the lithium acetate method ([@B69]). Four to eight single colonies were restreaked three consecutive times on selective media, and diagnostic PCRs were performed in order to verify their genotype. E. coli XL1-Blue was used for chemical transformation ([@B70]). Plasmids were then isolated and verified by either restriction analysis or by diagnostic PCR.

###### 

Oligonucleotide primers used in this study

  Primer ID   Sequence                                                                                                                   Product(s)[^*a*^](#T4F1){ref-type="table-fn"}
  ----------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  6005        GATCATTTATCTTTCACTGCGGAGAAG                                                                                                gRNA pROS plasmid backbone amplification
  6006        GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC                                                                                   gRNA pROS plasmid backbone amplification
  14229       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCAGTAGAATTTCACCTAGACGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for SynPAM gRNA plasmid
  13686       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCCTGCGGTGATAGAACCCTGGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *ABZ1* gRNA plasmid
  14988       CTTTTACACGATGACCTTTCGAGATTTCACAAGGGGGATAAAGGAAGTAGAATTTCACCTAGACGTGGATATTTGTATATTATTAGATATGTATGCAAACATTTTCTTTAGAA          *ABZ1* KO repair oligonucleotide
  14989       TTCTAAAGAAAATGTTTGCATACATATCTAATAATATACAAATATCCACGTCTAGGTGAAATTCTACTTCCTTTATCCCCCTTGTGAAATCTCGAAAGGTCATCGTGTAAAAG          *ABZ1* KO repair oligonucleotide
  13693       AAACCGCGAATATATAAAAACAAGC                                                                                                  *ABZ1* mutant allele amplification
  13694       GGCACAAAACGTCATTTTCC                                                                                                       *ABZ1* mutant allele amplification
  15075       TAATCACTCGGCAATGTGGAATTGTTACCGTGATAGCCTTCATGCAGTAGAATTTCACCTAGACGTGGATCTTATACCAATTTTATGCAGGATGCTGAGTGCTATTTGTTAGC          *ARO7* KO repair oligonucleotide
  15076       GCTAACAAATAGCACTCAGCATCCTGCATAAAATTGGTATAAGATCCACGTCTAGGTGAAATTCTACTGCATGAAGGCTATCACGGTAACAATTCCACATTGCCGAGTGATTA          *ARO7* KO repair oligonucleotide
  12052       CAGGAGTCTCTGAGCAAGGC                                                                                                       *ARO7* mutant allele amplification
  12053       ACCATGCTAAGAGCTGCTCC                                                                                                       *ARO7* mutant allele amplification
  15037       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCAGCATCAGAAGTAATAACAAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *BAS1* gRNA plasmid
  15584       AAACTTTTGTTGTAGCGTTTTTGCTTTTTTTTTTTTATCGCAGAATACATTTTATCGAGATAGGTCTAGAGATCTGTTTAGCTTGC                                     Repair fragment with hphNT1 for *BAS1* KO
  15585       ATTACAAAACTAATATGTTAAACAATTGAAAGATTTGTGTTTTTTTTCGGCCTTGCCTTCAGCTCCAGCTTTTGTTCCC                                            Repair fragment with hphNT1 for *BAS1* KO
  13687       CCTTTGACGATGTGCAACGG                                                                                                       Amplification *BAS1* mutant allele
  13688       AACGCCCTTTGTGTTTGTGG                                                                                                       Amplification *BAS1* mutant allele
  13520       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCTCTTGCTGGACGTATAATGGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *CNB1* gRNA plasmid
  13612       ACTCAATGGTGATCAGAATCCATAGAAGCATTTTTATTTCTTAAAAGTAGAATTTCACCTAGACGTGGGACTAGGGGACACTTCATTCATTTATGGTATGCCAATATTTTTAA          *CNB1* KO repair oligonucleotide
  13613       TTAAAAATATTGGCATACCATAAATGAATGAAGTGTCCCCTAGTCCCACGTCTAGGTGAAATTCTACTTTTAAGAAATAAAAATGCTTCTATGGATTCTGATCACCATTGAGT          *CNB1* KO repair oligonucleotide
  13523       GCATCAGCACTGCAGAATCG                                                                                                       *CNB1* mutant allele amplification
  13524       GATCCCCCTTTGTGCATTGC                                                                                                       *CNB1* mutant allele amplification
  13521       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCCATAAAAAGAGAGACCACTGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *PMR1* gRNA plasmid
  13541       CCAGCACAGACGTAAGCTTAAGTGTAAGTAAAAGATAAGATAATTAGTAGAATTTCACCTAGACGTGGTATGTCACATTTTGTGCTTTTATCGTTTTTCCTTCCTTCCCTTTA          *PMR1* KO repair oligonucleotide
  13542       TAAAGGGAAGGAAGGAAAAACGATAAAAGCACAAAATGTGACATACCACGTCTAGGTGAAATTCTACTAATTATCTTATCTTTTACTTACACTTAAGCTTACGTCTGTGCTGG          *PMR1* KO repair oligonucleotide
  11292       TCGCCCCGTTCTTTCCATTC                                                                                                       *PMR1* mutant allele amplification
  11293       GGGCGAAAAGGTAAGAACGC                                                                                                       *PMR1* mutant allele amplification
  13522       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCCATAAAAGAACATTGCACCAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *FRE2* gRNA plasmid
  13539       AATAAAGTCTTTTTTATCCAAAGCTTATGAAACCCAACGAATATAAGTAGAATTTCACCTAGACGTGGTCATTTTTTACTTAAAACTAGTCATTTCATTAATAATACCTATCC          *FRE2* KO repair oligonucleotide
  13540       GGATAGGTATTATTAATGAAATGACTAGTTTTAAGTAAAAAATGACCACGTCTAGGTGAAATTCTACTTATATTCGTTGGGTTTCATAAGCTTTGGATAAAAAAGACTTTATT          *FRE2* KO repair oligonucleotide
  13524       GATCCCCCTTTGTGCATTGC                                                                                                       *FRE2* mutant allele amplification
  13525       TGGCTCAATGATGCTAGTGGG                                                                                                      *FRE2* mutant allele amplification
  12174       GCATCGTCTCATCGGTCTCATATGTCTGCTACCTCTACTGCTACTTCC                                                                           *THI4* with YTK part 3 compatible overhangs
  12175       ATGCCGTCTCAGGTCTCAGGATCTAAGCAGCAAAGTGTTTCAAAATTTG                                                                          *THI4* with YTK part 3 compatible overhangs
  14586       ACAGTTTTGACAACTGGTTACTTCCCTAAGACTGTTTATATTAGGATTGTCAAGACACTCCAGTTCGAGTTTATCATTATCAATAC                                     *THI4*↑ cassette repair for integration
  14587       ATAATTATAATATCCTGGACACTTTACTTATCTAGCGTATGTTATTACTCGATAAGTGCTCGTTCAGGGTAATATATTTTAACC                                       *THI4*↑ cassette repair for integration
  13518       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCTGAATCTGGTGATAGCACCGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *GAL11* gRNA plasmid
  13533       TACTCAAAGATCAAGGATTAAAACGCTATTTCTTTTAAATCTGCTAGTAGAATTTCACCTAGACGTGGACATTTGAAGTTTCCATACTTTTGATACTTTTGAAGTTACTTCGT          *GAL11* KO repair oligonucleotide
  13534       ACGAAGTAACTTCAAAAGTATCAAAAGTATGGAAACTTCAAATGTCCACGTCTAGGTGAAATTCTACTAGCAGATTTAAAAGAAATAGCGTTTTAATCCTTGATCTTTGAGTA          *GAL11* KO repair oligo
  13498       TTCGAATCGGGCCTTCCTTC                                                                                                       *GAL11* mutant allele amplification
  13499       TGCTTGAAGTGGCACTTTGC                                                                                                       *GAL11* mutant allele amplification
  13517       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCTGGAAGGGTAGACCATGACAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *TUP1* gRNA plasmid
  13531       TGATAAGCAGGGGAAGAAAGAAATCAGCTTTCCATCCAAACCAATAGTAGAATTTCACCTAGACGTGGGAACAGAACACAAAAGGAACACTTTACAAATGTAACTAACTAAAC          *TUP1* KO repair oligonucleotide
  13532       GTTTAGTTAGTTACATTTGTAAAGTGTTCCTTTTGTGTTCTGTTCCCACGTCTAGGTGAAATTCTACTATTGGTTTGGATGGAAAGCTGATTTCTTTCTTCCCCTGCTTATCA          *TUP1* KO repair oligonucleotide
  15077       CACGCCAAGTTACCTTTCGC                                                                                                       *TUP1* mutant allele amplification
  15078       GGAAGGGATGAATGGTGAGG                                                                                                       *TUP1* mutant allele amplification
  13519       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCGAAAAAGAGAAGGCAAAACGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for *ISW2* gRNA plasmid
  13535       CTTGTTGGTTTAAGTCGTAACAAAAGGAAAACTTACAATCAGATCAGTAGAATTTCACCTAGACGTGGATCATGTATTGTGCATTAAAATAAGTGACGTGAGAGATATAATTT          *ISW2* KO repair oligonucleotide
  13536       AAATTATATCTCTCACGTCACTTATTTTAATGCACAATACATGATCCACGTCTAGGTGAAATTCTACTGATCTGATTGTAAGTTTTCCTTTTGTTACGACTTAAACCAACAAG          *ISW2* KO repair oligonucleotide
  13496       TCACCCAGAGGCAAAAGGTG                                                                                                       *ISW2* mutant allele amplification
  13497       TAGTTAAAGCGGCTCGACCC                                                                                                       *ISW2* mutant allele amplification
  16598       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCTCAAGATTGTCTTGTTCTTGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC   2-μm fragment for *FMS1* gRNA plasmid
  13527       AACAAGAAGTGAGTTAATAAAGGCAAAAACAGTGGTCGTGTGAGAAGTAGAATTTCACCTAGACGTGGAATCTATTTTTTCGAAATTACTTACACTTTTGACGGCTAGAAAAG          *FMS1* KO repair oligonucleotide
  13528       CTTTTCTAGCCGTCAAAAGTGTAAGTAATTTCGAAAAAATAGATTCCACGTCTAGGTGAAATTCTACTTCTCACACGACCACTGTTTTTGCCTTTATTAACTCACTTCTTGTT          *FMS1* KO repair oligonucleotide
  13525       TGGCTCAATGATGCTAGTGGG                                                                                                      *FMS1* mutant allele amplification
  13526       AGCCAAATTGCCAAGAAAGGG                                                                                                      *FMS1* mutant allele amplification
  16601       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCGCGTGAACGCAAATGCATCGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC   2-μm fragment for *SPE2* gRNA plasmid
  16602       AATAGTATTTTTCAGCGAGAATCATATTGGATGAGTATCCACATGGCGTGAACGCAAATGtATCGTGaTGAAATGATAAATCGGAGTCTTGGGCCGAGTTGACATATATTTCGTCAAG     *SPE2* mutation-carrying repair oligonucleotide
  16603       CTTGACGAAATATATGTCAACTCGGCCCAAGACTCCGATTTATCATTTCAtCACGATaCATTTGCGTTCACGCCATGTGGATACTCATCCAATATGATTCTCGCTGAAAAATACTATT     *SPE2* mutation-carrying repair oligonucleotide
  12174       GCATCGTCTCATCGGTCTCATATGTCTGCTACCTCTACTGCTACTTCC                                                                           YTK-compatible end addition to *THI4* CDS
  12175       ATGCCGTCTCAGGTCTCAGGATCTAAGCAGCAAAGTGTTTCAAAATTTG                                                                          YTK-compatible end addition to *THI4* CDS
  12985       TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCAAACATTCAAATATATTCCAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG                    2-μm fragment for YPRcTau3 gRNA plasmid
  13261       AATACGAGGCGAATGTCTAGG                                                                                                      *THI4* integration check
  13262       GCCTCCCCTAGCTGAACAAC                                                                                                       *THI4* integration check
  13492       TACAGCTCGCTCCTTGCATC                                                                                                       *SPE2* mutation check
  13493       GCTTGCTTGGAGGGCTTTTC                                                                                                       *SPE2* mutation check
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KO, knockout.

###### 

Plasmids used in this study

  Plasmid   Relevant characteristics                                          Reference
  --------- ----------------------------------------------------------------- ------------
  pROS12    colE1^ori^ 2-μm *bla hphNT1* gRNA-CAN1.Y gRNA-ADE2.Y              [@B11]
  pROS13    colE1^ori^ 2-μm *bla aph* gRNA-*CAN1*.Y gRNA-*ADE2*.Y             [@B11]
  pUDR412   colE1^ori^ 2-μm *bla* hphNT1 gRNA-ARO7 gRNA-ARO7                  [@B19]
  pYTK009   colE1^ori^ *cat pTDH3*                                            [@B74]
  pYTK056   colE1^ori^ *cat tTDH1*                                            [@B74]
  pYTK096   colE1^ori^ *aph URA3* 5′ homology *sfGFP URA3 URA3* 3′ homology   [@B74]
  pUDR388   colE1^ori^ 2-μm *bla aph* gRNA-*CNB1* gRNA-*CNB1*                 This study
  pUDR389   colE1^ori^ 2-μm *bla aph* gRNA-PMR1 gRNA-PMR1                     This study
  pUDR390   colE1^ori^ 2-μm *bla aph* gRNA-FRE2 gRNA-FRE2                     This study
  pUDR438   colE1^ori^ 2-μm *bla aph* gRNA-ABZ1 gRNA-ABZ1                     This study
  pUDR441   colE1^ori^ 2-μm *bla* hphNT1 gRNA-GAL11 gRNA-GAL11                This study
  pUDR471   colE1^ori^ 2-μm *bla aph* gRNA-SynPAM gRNA-SynPAM                 This study
  pUDR472   colE1^ori^ 2-μm *bla aph* gRNA-TUP1 gRNA-TUP1                     This study
  pUDR473   colE1^ori^ 2-μm *bla aph* gRNA-ISW2 gRNA-ISW2                     This study
  pUDR566   colE1^ori^ 2-μm *bla aph* gRNA-BAS1 gRNA-BAS1                     This study
  pUDR592   colE1^ori^ 2-μm *bla aph* gRNA-hphNT1 gRNA-hphNT1                 This study
  pUDR652   colE1^ori^ 2-μm *bla aph* MX gRNA-FMS1 gRNA-FMS1                  This study
  pUDR651   colE1^ori^ 2-μm *bla aph* gRNA-SPE2 gRNA-SPE2                     This study
  pUDR514   colE1^ori^ 2-μm *bla aph* gRNA-YPRcTau3 gRNA-YPRcTau3             This study
  pUDI180   colE1^ori^ *aph pTDH3-ScTHI4-tTDH1*                               This study
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Laboratory evolution. {#s4.3}
---------------------

Laboratory evolution of S. cerevisiae CEN.PK113-7D for fast growth in SMD medium lacking a single vitamin was performed by sequential transfer in aerobic shake-flask batch cultures. A frozen aliquot of strain CEN.PK113-7D was inoculated in a preculture shake flask containing SMD medium supplemented with all vitamins. Cells were then spun down, washed twice with sterile water, and used to inoculate a second shake flask containing SMD lacking one of the vitamins. The culture was then grown until stationary phase and transferred in a third shake flask containing the same fresh medium. At each transfer, 0.2 ml culture broth was transferred to 20 ml fresh medium, corresponding to approximately 6.7 generations in each growth cycle. The evolution experiment was performed in SMΔthiamine, SMΔpyridoxine, SMΔpantothenic acid, SMΔinositol, SMΔnicotinic acid, and SMΔpABA media. Each evolution experiment was performed in triplicates. After a defined number of transfers, intermediate strains were stocked and characterized for the growth rate. The experiment was stopped once the target specific growth rate of 0.35 h^−1^ was reached. From each evolved population, three single colonies were then isolated and stored. The specific growth rate of these single cell lines was measured to verify that they were representative of the evolved population. The best performing isolate from each evolution line was selected for whole-genome sequencing.

Shake flask growth experiments. {#s4.4}
-------------------------------

For specific growth rate measurements of strains (evolved populations as well as single cell lines), an aliquot was used to inoculate a shake flask containing 100 ml of fresh medium. For specific growth rate measurements of the engineered strains, a frozen aliquot was thawed and used to inoculate a 20-ml starter culture that was then used to inoculate the 100-ml flask. An initial optical density at 660 nm (OD~660~) of 0.1 or 0.2 was used as a starting point. The flasks were then incubated, and growth was monitored using a 7200 Jenway spectrometer (Jenway, Stone, United Kingdom). Specific growth rates were calculated from at least four time points in the exponential growth phase of each culture.

DNA sequencing. {#s4.5}
---------------

Genomic DNA of strains IMS0721, IMS0722, IMS0723, IMS0724, IMS0725, IMS0726, IMS0727, IMS0728, IMS0729, IMS0730, IMS0731, IMS0732, IMS0733, IMS0734, IMS0735, IMS0736, IMS0737, IMS0738, IMS0747, IMS0748, IMS0749, IMX2128, IMX2135, IMX2136, and IMX2137 was isolated with a Blood & Cell Culture DNA kit with 100/G Genomic-tips (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Illumina-based paired-end sequencing with 150-bp reads was performed on 300-bp insert libraries (Novogene \[HK\] Company Limited, Hong Kong) with a minimum resulting coverage of 50×. Data mapping was performed against the CEN.PK113-7D genome ([@B23]) where an extra chromosome containing the relative integration cassette was previously added. Data processing and chromosome copy number variation determinations were conducted as previously described ([@B60], [@B71]).

Plasmid cloning. {#s4.6}
----------------

Plasmids carrying two copies of the same genomic RNA (gRNA) were cloned by *in vitro* Gibson assembly as previously described ([@B72]). In brief, an oligonucleotide carrying the 20-bp target sequence and homology to the backbone plasmid was used to amplify the fragment carrying the 2-μm origin of replication sequence by using pROS13 as the template. The backbone linear fragment was amplified by using primer 6005 and either pROS12 or pROS13 as the template ([@B73]). The two fragments were then gel purified, combined, and assembled *in vitro* using the NEBuilder HiFi DNA Assembly master mix (New England BioLabs, Ipswich, MA) according to the manufacturer's instructions. Transformants were selected on LB plates supplemented with 100 mg/liter ampicillin.

Primers 13520, 13521, 13522, 13686, 13518, 14229, 13517, 13519, 15037, 15728, 12985, 16598, and 16601 were used to amplify the 2-μm fragments targeting *CNB1*, *PMR1*, *FRE2*, *ABZ1*, *GAL11*, SynPAM, *TUP1*, *ISW2*, *BAS1*, hphNT1, YPRcTau3, *FMS1*, and *SPE2*, respectively. The fragment targeting *GAL11* was cloned in a pROS12 backbone yielding plasmid pUDR441. The fragments targeting *CNB1*, *PMR1*, *FRE2*, *ABZ1*, SynPAM, *TUP1*, *ISW2*, *BAS1*, hphNT1, YPRcTau3, *FMS1*, and *SPE2* were cloned in a pROS13 backbone yielding plasmids pUDR388, pUDR389, pUDR390, pUDR438, pUDR471, pUDR472, pUDR473, pUDR566, pUDR592, pUDR514, pUDR652, and pUDR651, respectively.

The plasmid carrying the expression cassette for *THI4* was cloned by golden gate assembly using the yeast toolkit (YTK) parts ([@B74]). The *THI4* coding sequence was amplified using the primer pair 12174/12175 and CEN.PK113-7D genomic DNA as a template in order to add YTK compatible ends to the gene. The PCR product was then purified and combined together with plasmids pYTK009, pYTK056, and pYTK096 in a BsaI golden gate reaction that yielded plasmid pUDI180.

Strain construction. {#s4.7}
--------------------

Strains carrying the target mutations were all constructed starting from IMX585 expressing the Cas9 protein ([@B73]). For all strain except for IMX2290, IMX2291, IMX2289, and IMX2308, a two-step strategy was adopted where first the target gene to be mutated was removed and replaced with a synthetic and unique 20-bp target sequence plus 3-bp PAM sequence (SynPAM), and then the synthetic target sequence was targeted and replaced with the mutant gene. In the second step where the SynPAM sequence was targeted, the mutant gene flanked by about 400-bp upstream and downstream sequences was amplified by using the evolved strain genomic DNA as the template. The PCR product was then gel purified and used as a repair fragment in the transformation. This strategy yielded both intermediate strains lacking the targeted gene and final strains carrying the desired mutant gene.

In the first step, IMX585 was targeted at the gene of interest by transforming the strain with the relative pUDR plasmid. The double-strand break was then repaired by cotransforming the strain with two cDNA oligonucleotides carrying the SynPAM sequence flanked by 60-bp homology sequences to the targeted *locus* that were previously combined at a 1:1 molar ratio, boiled for 5 min, and annealed by cooling down the solution at room temperature on the bench.

Five hundred nanograms of annealed primer pairs 13612/13613, 13541/13542, 13539/13540, 14988/14989, 15075/15076, 13533/13534, 13531/13532, 13535/13536, and 13527/13528 were cotransformed with 500 ng pUDR388, pUDR389, pUDR390, pUDR438, pUDR412, pUDR441, pUDR472, pUDR473, and pUDR652, respectively, yielding IMX1721, IMX1722, IMX1723, IMX1988, IMX1820, IMX1819, IMX1817, IMX1818, and IMX2292, respectively. IMX1819 and IMX1820 transformants were selected on YPD plates with 200 mg/liter hygromycin, while IMX1721, IMX1722, IMX1723, IMX1988, IMX1817, IMX1818, and IMX2292 transformants were selected on YPD plates with 200 mg/liter G418.

The *BAS1* knockout strain could not be obtained with the marker-free SynPAM strategy. Therefore, the hphNT1 marker cassette was amplified by using primers 15584/15585 to add 60-bp homology flanks and pROS12 as a template. The PCR fragment was then gel purified, and 500 ng was cotransformed with 500 ng pUDR592 to yield IMX2128. Transformants were selected on YPD plates with 200 mg/liter G418 and 200 mg/liter hygromycin.

In the second step, the SynPAM target sequence in each knockout strain was targeted for the insertion of the mutant allele. The mutant gene flanked by approximately 400-bp upstream and downstream sequences was amplified using the evolved strain genomic DNA as the template. The PCR product was then gel purified, and 500 ng was cotransformed with 500 ng of pUDR471. Primer pairs 13523/13524, 11292/11293, 13525/13526, 12052/12053, 11725/11726, 13498/13499, 13498/13499, 15077/15078, 15077/15078, 13496/13497, and 13527/13528 were used to amplify the mutant alleles of *CNB1*^L82F^, *PMR1*^S104Y^, *FRE2*^T110S^, *ARO7*^L205S^, *ABZ1*^R593H^, *GAL11*^I541N^, *GAL11*^Q383stop^, *TUP1*^V374A^, *TUP1*^Q99stop^, *ISW2*^S181stop^, and *FMS1*^Q33K^, respectively, using IMS0747, IMS0748, IMS0748, IMS0728, IMS0727, IMS0734, IMS0735, IMS0734, IMS0735, IMS0733, and IMS0735 genomic DNA as the templates, respectively. Transformants were selected on YPD plates with 200 mg/liter G418, yielding IMX1985, IMX1986, IMX1987, IMX1989, IMX2057, IMX1991, IMX1992, IMX2002, IMX2003, IMX1990, and IMX2292, respectively. The *BAS1*^Q152R^, *BAS1*^D101N^, and *BAS1*^S41P^ mutant alleles were amplified from IMS736, IMS737, and IMS738 genomic DNA, respectively, using the primer pair 13687/13688. After gel purification, 500 ng of each PCR product was cotransformed in IMX2128, together with the hphNT1-targeting plasmid pUDR650, yielding IMX2135, IMX2136, and IMX2137, respectively. The strain IMX2289 carrying the *SPE2*^A278T^ mutant allele was constructed by transforming IMX585 with the *SPE2*-targeting plasmid pUDR651 together with the annealed primer pair 16602/16603 containing the desired single base change plus a synonymous mutation causing the removal of the PAM sequence. After transformation, strains IMX2135, IMX2136, IMX2137, and IMX2289 were plated on YPD plates with 200 mg/liter G418 for selection.

Mutant alleles found in the same evolved strains were combined in a single strain by repeating the strategy described above but this time using a mutant strain as a starting point instead of IMX585. In this way, *GAL11*, *TUP1*, and *FMS1* were deleted in IMX2002, IMX2003, and IMX2127, respectively, by cotransforming the relative gRNA plasmid and the relative double-stranded DNA (dsDNA) oligonucleotide pair as performed for the single-knockout strains, yielding the intermediate strains IMX2066, IMX2110, and IMX2294, respectively. Then, the SynPAM sequence was targeted in IMX2066, IMX2110, and IMX2294 as previously described for the single mutant strains, yielding IMX2087, IMX2127, and IMX2307, respectively. IMX2043 carrying the *PMR1*^S104Y^-*FRE2*^T110S^ double mutation was constructed by cotransforming IMX1987 with pUDR390 and the linear fragment containing the *FRE2*^T110S^ mutant allele that was previously amplified as described above. The *SPE2*^A278T^ mutant allele was combined with the *GAL11*^I541N^ *TUP1*^V374A^ mutant alleles present in IMX2127 by cotransforming the strain with the *SPE2*-targeting plasmid pUDR651 together with the annealed primer pair 16602/16603, yielding IMX2308. The *THI4* overexpression cassette was amplified by using pUDI180 as a template and primers 12174/12175. Five hundred nanograms of gel-purified PCR product was cotransformed together with the YPRcTau3-targeting plasmid pUDR514 in IMX585 and IMX1985 yielding IMX2290 and IMX2291, respectively.

To verify the correct gene editing, single colonies were picked from each transformation plate and genomic DNA was extracted as previously described ([@B68]). The targeted locus was amplified by PCR and run on a 1% agarose gel. Primers pair 13523/13524, 13541/13542, 13539/13540, 15077/15078, 13496/13497, 13498/13499, 12052/12053, 13523/13524, 13541/13542, 13539/13540, 13693/13694, 12052/12053, 13496/13497, 13498/13499, 13498/13499, 15077/15078, 15077/15078, 13524/13525, 13693/13694, 13498/13499, 15077/15078, 15077/15078, 13687/13688, 13498/13499, 13687/13688, 13687/13688, 13687/13688, 13261/13262, 13261/13262, 13492/13493, 13525/13526, 13525/13526, 13492/13493, and 13525/13526 were used to verify the correct gene editing in IMX1721, IMX1722, IMX1723, IMX1817, IMX1818, IMX1819, IMX1920, IMX1985, IMX1986, IMX1987, IMX1988, IMX1989, IMX1990, IMX1991, IMX1992, IMX2002, IMX2003, IMX2043, IMX2057, IMX2066, IMX2110, IMX2127, IMX2128, IMX2087, IMX2135, IMX2136, IMX2137 IMX2290, IMX2291, IMX2289, IMX2292, IMX2306, IMX2308, and IMX2307, respectively. To verify the presence of the single point mutations, each PCR product was purified and Sanger sequenced (Baseclear, The Netherlands). Mutations in *BAS1* could not be verified by Sanger sequencing; therefore, whole-genome resequencing of IMX2135, IMX2136, and IMX2137 was performed as explained above for the evolved single-colony isolates.

After genotyping of the transformants, correct isolates were grown in 20 ml YPD in a 50-ml vented Greiner tube at 30°C overnight by inoculating a single colony. The next day, 1 μl was transferred to a new tube containing the same amount of medium and the sample was grown overnight. The day after, each liquid culture was restreaked to single colony by plating on YPD agar plates. Plates were incubated at 30°C overnight, and the next day, single colonies were patched on both YPD and YPD plus the relative antibiotic (either G418 or hygromycin) to assess which clones had lost the gRNA plasmid. One clone for each strain that had lost the plasmid was then grown in YPD, and 30% (vol/vol) glycerol was added prior to stocking samples at −80°C.

Data availability. {#s4.8}
------------------

The sequencing data of the evolved and of the *BAS1* deletion Saccharomyces cerevisiae strains were deposited at NCBI (<https://www.ncbi.nlm.nih.gov/>) under BioProject accession number [PRJNA603441](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA603441). All measurement data used to prepare the figures of the manuscript are available at the data.4TU.nl repository (<https://doi.org/10.4121/uuid:53c9992f-d004-4d26-a3cd-789c524fe35c>).
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